September 10, 2025Zeitschrift für Gastroenterologie

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis Delta with and without virologic response

View Full Paper

Ask AI

Bookmark

Authors

MBMaurizia BrunettoUniversity of Pisa SASoo AlemanKarolinska University Hospital PAPietro AndreonéUniversity of Modena and Reggio Emilia

Discussion

Member takes

Implication

Observational analysis shows improved hepatic function in chronic hepatitis delta patients, indicating effectiveness of bulevirtide therapy for liver disease burden.

Key Points

Bulevirtide therapy improves noninvasive test outcomes, enhancing liver disease management.
After 144 weeks, studies indicate significant improvement in test results for patients with chronic hepatitis delta.
Patients receiving bulevirtide therapy showed improved hepatic function and reduced disease burden.
This analysis provides evidence supporting the efficacy of bulevirtide, suggesting benefits even in cases without virologic response.

Cite This Study

Brunetto et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478b043 https://doi.org/10.1055/s-0045-1810984

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows improved hepatic function in chronic hepatitis delta patients, indicating effectiveness of bulevirtide therapy for liver disease burden.

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis Delta with and without virologic response

Discussion

Member takes

Implication

Key Points

Cite This Study

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis Delta with and without virologic response

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider